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Background: Antimicrobial resistant Salmonella is a global problem and recently, a strain on the verge of
pan-resistance was reported. In Ethiopia, the therapeutic management of Salmonellosis is difficult because drug
sensitivity tests are not routinely carried out and treatment alternatives are not available in most health care
facilities. The objectives of this study were to estimate the temporal changes and proportions of drug resistant
isolates in Ethiopia.
Methods: Published studies on drug resistant Salmonella isolates were searched in Medline, Google Scholar and
the lists of references of articles. Eligible studies were selected by using inclusion and exclusion criteria. Generic,
methodological and statistical information were extracted from the eligible studies. The extracted data included the
proportions of ampicillin, co-trimoxazole, chloramphenicol, ceftriaxone, ciprofloxacin and multi-drug resistant
isolates. Pooled proportions were estimated by a random effects model.
Results: The odds of multi-drug resistant isolates in the 2000s was higher than before the 1990s (OR =18.86,
95% CI = 13.08, 27.19). The pooled proportions of ampicillin, co-trimoxazole, chloramphenicol, ciprofloxacin and
multi-drug resistant isolates in the 2000s were 86.01%, 68.01%, 62.08%, 3.61% and 79.56% respectively. S. Concord
(>97%) was resistant to ampicillin, co-trimoxazole, chloramphenicol and ceftriaxone.
Conclusion: The proportion of drug resistant isolates has increased since the 1970s. All drugs currently used for the
treatment of Salmonellosis but ciprofloxacin are not reliable for an empirical therapy. Alternative drugs should be
included in the essential drug list and measures should be taken to re-enforce the drug use policy.
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The emergence of drug resistant pathogens is associated
with a variety of biological, pharmacological and societal
variables with the worst combinations in developing
countries [1]. Antimicrobial resistant Salmonella is one
of the global problems in present day clinical practices
and recently, a strain on the verge of pan-resistance was
reported [2]. In sub-Saharan Africa (SSA), the prevalence
of MDR Salmonella has increased and outbreaks due to
MDR strains were recorded [3-5]. Infections with MDR
pathogens are associated with excess morbidity and mor-
tality probably because of the co-selection of traits of drug
resistance and virulence [6]. In developing countries like
Ethiopia, the therapeutic management of the disease isCorrespondence: getadesse1@yahoo.com
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unless otherwise stated.difficult because drug sensitivity tests are not routinely
carried out and treatment alternatives are not available
in most health care facilities.
Salmonella is one of the major causes of gastroenteritis
and fever in Ethiopia. The bacterium was isolated from a
number of patients including pediatrics [7] and mal-
nourished children [8]. S. Concord, S. Typhi, S. Typhimu-
rium and S. Paratyphi were the dominant serotypes that
accounted for 82.1% of the isolates from patients [9].
S. Concord was isolated from a bone processing plant
[10], an immigrant in Ireland [11], diarrheal and/or febrile
patients [12,13] and Ethiopian adoptees in Europe and the
USA [14-16] but its occurrence in other countries in SSA
is reportedly low [17]. Typhoidal Salmonella was the sec-
ond common isolate [9] and a case fatality rate of 15.7%
was recorded in hospital admitted children [18]. In 2006,
typhoid fever was diagnosed in 37(6.7%) febrile childrenThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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SSA [17-19], highly invasive [20-22] and causes high
mortality in AIDS patients [23].
Despite the importance of the disease, surveillance and
monitoring systems are not in place and the pharmaco-
epidemiology of the bacteria is not adequately described.
However, integration of previous estimates could provide
an insight into the temporal changes and the propor-
tions of drug resistant isolates. The objectives of this
study were to quantify the temporal changes and esti-
mate the proportions of drug resistant isolates by using
meta-analytical methods.
Methods
The study was conducted according to the guideline of
the PRISMA group (Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses) [24]. The PRISMA
check list was used to ensure inclusion of relevant infor-
mation (Additional file 1). The outcomes of interest were
the proportions of ampicillin, co-trimoxazole, chloram-
phenicol, ceftriaxone, ciprofloxacin and multi-drug resist-
ant isolates. MDR was defined as resistance to three or
more drugs.
Literature search and eligibility criteria
The literature search strategy is described in a previous
report [9]. Briefly, studies were searched in Medline,
Google scholar and the lists of references of articles. The
last search was done on March 30, 2014. To be eligible,
a study had to be (i) published, (ii) written in English
and (iii) cross sectional or retrospective. Initially, studies
with titles and abstracts that are not relevant to the out-
comes of interest were excluded. Of the screened arti-
cles, duplicates and studies that reported small number
of isolates (1-22) were excluded.
Data extraction
The first author, year of study, location, study design,
antimicrobial test methods and interpretative standards,
numbers of isolates and numbers of drug resistant iso-
lates were extracted. If the proportion of drug sensitive
isolates (q) was reported, the number of resistant isolates
was calculated by multiplying the number of isolates (n)
by one minus the proportion of drug sensitive isolates
(1-q). The study level proportions were derived from the
extracted data. The data was abstracted by TG.
Data analysis
A zero reported for the numbers of drug resistant or
sensitive isolates was imputed as 0.5 [25]. The proportions
and standard errors were calculated by the following for-
mulae: p = r/n and s. e. =√ p (1-p)/n, where r = number of
resistant isolates and n = number of isolates. To normalize
the distribution of the data, the proportions weretransformed to logit event estimates [26,27]: lp = ln [p/
(1 − p)], where lp = logit event estimate; ln = natural
logarithm; p = study level estimate. The variances were
calculated by the following formula: v (lp) = 1/ (np) + 1/[n
(1 − p)], where v = variance and n = sample size.
Bias and heterogeneity analyses
The antimicrobial test methods and the interpretative
standards (break point levels) were examined to assess the
within study biases. Funnel plots were used to get visual
impressions of the across study biases (small study ef-
fects). The Begg and Mazumdar adjusted rank correlation
and the Egger’s regression asymmetry tests were used to
test the significance of funnel plots’ asymmetries.
Heterogeneities were assessed by the Galbraith plot
and the Cochran’s Q test. The percentage of the vari-
ation attributable to heterogeneity was quantified by the
inverse variance index (I2) [28]. As the power of the
Cochran’s Q test is low in small number of studies, stu-
dies were considered heterogeneous if the ratio of Q and
the degree of freedom was greater than one. I2 values of
25% 50% and 75% were considered as low, moderate and
high heterogeneity respectively.
Temporal change and trend analyses
The average temporal changes were estimated by using a
meta-regression model: y = a + bx + u + e; where a = con-
stant, b = regression coefficient, x = year of study, u =
error term with known standard deviation and e = error
term of the additive component of the variance (tau2). If
two or more calendar years were reported, the median
was considered as year of study. Tau2 was estimated by
the methods of moments. The Knapp-Hartung variance
modification factor was used to calculate the probability
values and confidence intervals of the coefficients. The
Mantel extension Chi Square for trend was used to as-
sess the changes in the proportion of MDR isolates
across decades (1970s/80s, 1990s and 2000s).
Pooling and sensitivity tests
The DerSimonian and Laird random effects model was
used to pool logit event estimates [29]. Pooled logit esti-
mates were back-transformed to proportions by the fol-
lowing formula: p = elp/(elp + 1), where p = proportion
and e = the base of the natural logarithm. Single study
omitted influence analyses were done to assess the sensi-
tivities of pooled estimates. A study was considered to
be influential if the pooled estimate without it was not
within the 95% confidence bounds of the overall mean.
The statistical significance of a difference between pro-
portions was assessed by the Yates corrected Chi Square
test [30,31]. Alpha was set at 0.05.
Microsoft Office Excel 2007 was used to calculate study
level proportions, logit event estimates, standard errors
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tions. Epi info™ (Version 3.5.1, Center for Disease Control,
CDC, USA) was used to assess the trend and compare
proportions. All other analyses were done by using Stata
(Version 11.1, Stata Corp, College Station, Texas).
Results and discussion
Literature search and eligible studies
Figure 1 presents the search results. The search
yielded 140 studies. The titles and abstracts of 112
studies were not relevant to the outcomes of interest.
Of the articles screened for eligibility, 14 were ex-
cluded: one study was not available; three were du-
plicates and ten reported small numbers of isolates.
Fourteen studies were eligible for quantitative syn-
theses. Eleven studies were used to estimate the tem-
poral changes and trends [12,13,32-40]. Five studies
[13,37-40] were used to estimate the proportions of
drug resistant isolates in the 2000s. Four studies were
used to estimate the proportions of drug resistant S.
Concord in the 2000s [13-15,41]. In the 2000s, only
two studies reported the drug resistance features of 15
S. Typhi, two S. Paratyphi and seven S. Typhimurium
[13,37]. The search was comprehensive and most, if
not all published reports were considered in the
analysis. With the exception of one review on S. Typhi
[42], a review on the antimicrobial resistance features
of human Salmonella isolates in Ethiopia was not
found.Figure 1 A flow diagram of the selection of eligible studies.Characteristics of the eligible studies
The studies were carried out between 1974 and 2009 in
Central, Northern, Southern and Eastern Ethiopia
(Table 1). Three studies were on S. Concord isolated
from Ethiopian adoptees in Europe and the USA. A total
of 1030 isolates were tested with a variety of antimicro-
bials that included the penicillins, cephalosporins,
phenicols, quinolones, aminoglycosides, tetracyclines,
macrolides and peptides.
Risks of bias and heterogeneity
The disk diffusion method was reported in 11 studies
[12,13,32-40]. The micro-broth dilution method [14,41]
and the Episilon test (E-test) were used to determine
minimum inhibitory concentrations (MIC) [13]. Five
studies [12,32,33,35,36] used the breakpoint levels of
Bauer et al. 1966 [43] and nine studies used the stan-
dards of NCCLS (National Committee for Clinical and
Laboratory Standards) or CLISI (Clinical and Laboratory
Standards Institute) [13-15,34,37-41]. The DTU (Tech-
nical University of Denmark) food defined resistance
break point levels were used to assess resistance to cef-
tiofur, florfenicol and aminoglycosides [14]. In five stud-
ies carried out before 2000, the proportions of ampicillin
resistant isolates were underestimated because the
breakpoint level (11 mm or less) was lower than the
level (13 mm or less) in the modified versions. Simi-
larly, differences in the break point levels of drugs such
as tetracycline (14 mm or less in Bauer et al. 1966 [43]
Table 1 Characteristics of the eligible studies
Author Location Ys n Number of resistant isolates (%)
Amp Sxt Chl Cro Cip MDR
[12] AA 1974-1981 216 nr 0(0) nr nt nt 39(18.1)
[32] AA 1975-1980 165 22(13.3) 0(0) 19(11.5) nt nt 23(13.9)
[33]a AA 1982-1983 45 12(26.7) 0(0) 8(17.8) nt nt 10(22.2)
[34]b AA 1992-1993 37 30(81.1) 28(75.7) 31(83.8) nt nt 30(81.1)
[35] AA 1993-1996 110 40(36.4) 57(51.8) 39(35.5) nt nt 41(37.3)
[36]b AA 1995 45 31(68.9) 26(57.8) 21(46.7) nt nt 26(57.8)
[37] JM 2000 59 35(59.3) 24(40.7) 21(35.6) nt nt 45(76.3)
[38]b GD 2003-2005 59 54(91.5) 38(64.4) 46(78.0) nt 6(10.2) 46(78)
[13]b AA/JM 2004-2006 113 93(82.3) 91(80.5) 92(81.4) 89(78.8) 1(0.9) 91(80.5)
[39] BD 2003-2008 84 77(91.7) 67(79.8) 37(44.1) nt nt 72(85.7)
[40]c HR 2007 28 28(100) nt 18(64.3) nt nt 20(71.4)
[41]d,e DM 2007-2009 8 8(100) 8(100) 8(100) 8 (100) 0(0) 8(100)
[14]d,e, EU/USA 2003-2007 35 34(97.1) 35(100) 35(100) 34(97.1) 0(0) 35(100)
[15]d,e BL 2006-2009 26 26 (100) 26(100) 26(100) 26(100) 0(0) 26(100)
AA = Addis Ababa; AA/JM = Addis Ababa and Jimma; Amp = ampicillin; BD = Bahirdar; BL = Belgium; Chl = chloramphenicol; Cip = ciprofloxacin; Cro = ceftriaxone;
DM = Denmark; ET = Ethiopia; EU/USA = Europe and the United States of America; HR = Harar; JM = Jimma; GD = Gondar; n = number of isolates; nr = not reported;
nt = not tested; Sxt = co-trimoxazole; Ys = Year of study.
aThe numbers of chloramphenicol and ampicillin resistant isolates were derived from the proportions of sensitive isolates.
bThe third highest mono-drug resistant isolates number was considered as the number of MDR isolates assuming that the prevalence of MDR isolates is mainly a
reflection of the highly resisted drugs.
cData on amoxicillin was substituted to ampicillin assuming that the mechanism of resistance could be similar.
dThe data show the proportions of drug resistant S. Concord.
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Figure 2 Funnel plots of the logit event estimates (lp):
ampicillin (A), co-trimoxazole (B), chloramphenicol (C) and
multi-drug (D) resistant isolates.
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affected the proportions of MDR isolates. However, as
the occurrence of drug resistant isolates in the earlier
years was comparatively lower than in the 2000s, the
risks of underestimation or overestimation of the study
level proportions are negligible.
Figure 2 presents funnel plots of the estimates. The
plots demonstrate different patterns. The Egger’s bias
coefficients for ampicillin, co-trimoxazole, chloram-
phenicol and MDR estimates were 7.04 (95%CI = -1.67,
15.76), p > 0.05; -4.12 (95% CI = -8.32, 0.08), p > 0.05;
4.54 (95% CI = -8.72, 17.81), p > 0.05 and 11.06 (95%
CI = 0.09, 22.04), p > 0.05 respectively and the prob-
ability values calculated by the Begg and Mazmudar
test were greater than 5%. The plots and tests did not
suggest the presence of bias.
Figure 3 depicts forest plots of the proportions of drug
resistant isolates. The percentages of the variations of
the logit event estimates attributable to heterogeneities
are presented in Tables 2 and 3. The heterogeneities
could be mainly due to increases in the proportions of
resistant isolates across years.
Temporal changes and trend
Figure 4 presents regression plots of the logit event esti-
mates of drug resistant isolates against years of studies. The
plots demonstrate increasing patterns. The percentages ofthe explained variances were more than 41% (Table 2).
The proportions of MDR isolates differ by decade (X2 for
trend = 301.82; p < 001). Compared to the 1970/80s, MDR
isolates occurred more frequently in the 1990s (OR = 6.92,
95% CI = 4.73, 10.11) and 2000s (OR =18.86, 95% CI =
13.08, 27.19). The pooled proportion of MDR isolates in
the 2000s was higher than the proportion in the 1990s
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Figure 3 Forest plots of the proportions of drug resistant isolates.
Table 2 Temporal changes of the proportions of drug
resistant isolates
Drug I2 residuals Adjusted R2 b(95% CI) p
Ampa 82.62 77.58 0.54(0.52, 0.55) 0.001
Sxtb 72.31 89.52 0.53(0.52, 0.54) 0.000
Chla 84.73 41.05 0.55(0.52, 0.58) 0.003
MDRb 88.37 55.32 0.52(0.50, 0.54) 0.021
Amp = ampicillin; b = coefficient of year of study; Chl = chloramphenicol;
I2 = inverse variance index; MDR = multi-drug resistance; R2 = proportion of
explained variance; Sxt = co-trimoxazole.
aThe estimates were derived from data extracted from 10 studies [13,32-40].
bThe estimates were derived from data extracted from 10
studies [12,13,32-39].
Table 3 Pooled proportions of drug resistant Salmonella
isolated between 2000 and 2008
Drug Pooled estimate Heterogeneity
p(95% CI) Z-p Q Q-p Q/df I2
Amp 86.01(70.77, 93.98) 0.000 29.32 0.000 7.3 86.4
Sxt 68.01(48.13, 82.98) 0.075 31.54 0.000 10.5 90.5
Chl 62.08(41.05,79.38) 0.258 49.38 0.000 12.4 91.9
Cip 3.61(0.32, 30.62) 0.009 5.7 0.02 5.7 81.5
MDR 79.56(74.90, 83.54) 0.000 3.60 0.464 0.9 0.0
Amp = ampicillin; Chl = chloramphenicol; Cip = ciprofloxacin; df = degree of
freedom; I2 = inverse variance index; Q = Cochran’s X2; Q-p = probability value
of Cochran’s Q test; Sxt = co-trimoxazole; Z-p = probability value of Z test.







































Figure 4 Regression plots of the logit event estimates (lp)
against years of studies: ampicillin (A), co-trimoxazole (B),
chloramphenicol (C) and multi-drug (D) resistant isolates.
Table 4 Pooled proportions of drug resistant S. Concord
Drug Pooled proportiona Hetetrogeneity
p(95% CI) Z-p Q Q-p Q/df I2
Amp 98.68(94.85,99.67) 0.000 0.09 0.954 0.05 0.0
Sxt 98.68(94.85,99.67) 0.000 0.09 0.954 0.05 0.0
Chl 97.98(93.92,99.35) 0.000 0.20 0.903 0.1 0.0
Cro 97.98(93.92,99.35) 0.000 0.20 0.903 0.1 0.0
MDR 98.68(94.85,99.67) 0.000 0.09 0.954 0.05 0.0
Amp = ampicillin; Chl = Chloramphenicol; Cro = ceftriaxone; df = degrees of
freedom; Q = Cochran’s X2; Q-p = probability value of the Cochran’s Q test;
Sxt = co-trimoxazole; Z-p = probability value of the Z test.
aThe estimates were based on four studies [13-15,41]. Data from two studies
[14,41] were combined before pooling. Intermediate resistance to ciprofloxacin
was recorded in twelve isolates [14,41].
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lates could be due to the irrational use of antimicrobials.
Several studies have reported the inappropriateness of
the prescription and dispensing methods in both the
public and private health set-ups. For instance, in Northern
Ethiopia, Gondar, ampicillin and penicillin G were two
of the three commonly dispensed antimicrobials and
most drugs were prescribed by young interns and dis-
pensed by less qualified personnel [44]. In Southern
Ethiopia, Hawassa, amoxicillin, ampicillin, chlorampheni-
col, penicillin G and ceftriaxone were the most commonly
prescribed antibacterials [45]. Moreover, the prescriptions
had little justifications [46] and the proportion of patients
exposed to antimicrobials (>58%) [45-49] was com-
paratively higher than the standard (20.0%-26.8%) [50].
The pediatric age group was more exposed to antimi-
crobials than adults and the differences between the
prescription behaviors of personnel with shorter and
longer pre-service trainings and between public and pri-
vate health facilities were not significant [47]. Further-
more, prescription-only medications were dispensed
without a medical prescription; verbal instructions (87%)
were practiced in both pharmacies and rural drug vendors
[51] and several patients medicate themselves [52]. Es-
sential drug lists, standard treatment guidelines and
drug formulary were available in some but not in all
health care settings [53]. In general, the prescription
and dispensing practices are not consistent with the ra-
tional antimicrobial use guideline and could have fa-
vored the selection of antimicrobial resistant microbes.
Pooled proportions
Table 3 presents the pooled estimates of drug resistant
isolates in the 2000s. More than half of the isolates were
resistant to ampicillin, co-trimoxazole and chloram-
phenicol. All single study omitted pooled estimates werewithin the 95% confidence limits of the respective over-
all means. The pooled estimates show the magnitude of
the problem and the unreliability of ampicillin, co-
trimoxazole and chloramphenicol as empirical thera-
peutic agents. Moreover, the occurrences of isolates
resistant to ceftriaxone, 89(78.8%) [13] and norfloxacin,
13(15.5%) [39] were reported.
The higher prevalence of MDR isolates could be asso-
ciated with the presence of Class I integrons in several
isolates. Class I integrons were identified in 52 (53.1%)
MDR Salmonella predominantly of animal origin [54]
and in S. Concord with extended spectrum β-lactamase
genes (blaCTX-M-15) [16]. As data on the genetic
features of isolates of human origin is limited, further
genetic characterization of isolates is important to
understand evolving and epidemic prone strains.
Dominant serotypes
Table 4 presents pooled proportions of drug resistant
S. Concord. The MDR profiles are shown in Table 5. Be-
fore the 1990s, more than 81% of the isolates were resist-
ant to ampicillin, co-trimoxazole and chloramphenicol
[12]. However, in the 2000s more than 97% of the isolates
were resistant to the older antimicrobials including the
cephalosporins. Furthermore, resistance to aztreonam
[14], nalidixic acid [13,15] and intermediate resistance to
ciprofloxacin were recorded [14,15,41]. As is the case of
S. Kentucky [2], S. Concord appears to have taken several
steps to become pan-resistant and given its higher oc-
currence and invasiveness (30.6%) [13], it might have
caused considerable morbidities and mortalities in
Ethiopian children.
Data on the sensitivities of S. Typhi, S. Paratyphi and
S. Typhimurium are limited. However, there are evi-
dences on the occurrence of isolates that are resistant to
the older drugs [13,37] and norfloxacin [55]. In addition,
S. Typhimurium isolates of animal origin were shown to
be resistant to several drugs including ceftiofur and cip-
rofloxacin [56-61]. Furthermore, MDR genes located on
Table 5 MDR features of S. Concord
Author MDR profiles No. (%)
[13]a Amp Chl Cro Gen Sxt 41(48.8)
Amp Chl Cro Gen Sxt Tet 29(34.5)
Amp Chl Cro Gen Nal Sxt Tet 5(6.0)
[14]b Amp Azt Chl (Cep Cfp Cfr Cft Cfz Cpo Cro Ctz )
Str SulTmp
34(97.1)
Amp Azt Chl (Cep Cfp Cfr Cft Cfz Cpo Ctz )
Str SulTmp
1(2.9)
[15]c Amp Chl Cro Gen Str Sul Sxt Tmp 3(11.5)
Amp Chl Cro Gen Sul Str Sxt Tet Tmp 19(73.1)
Amp Chl Cro Gen Nal Str Sul Sxt Tet Tmp 4(15.4)
[41]d Amp Chl Cfo Cro Gen Str Sul Tet Tmp 8 (100)
Amp = ampicillin; Azt = aztreonam; Cep = cephalothin; Cfo = cefotaxime; Cfp =
cefepime; Cfr = cefuroxime; Cft = ceftiofur; Cfz = cefazolin; Cpo = cefpodoxime;
Cro = ceftriaxone; Ctz = ceftazidime; Chl = chloramphenicol; Gen = gentamicin;
Nal = nalidixic acid; Sul = sulfamethoxazole; Str = streptomycin; Sxt = co-
trimoxazole; Tet = tetracycline; Tmp = trimethoprim.
aEach profile was recorded in more than 5% of the MDR isolates. One isolate
was resistant to ofloxacin.
bResistance to gentamicin (97%), tetracycline (69%) and intermediate
resistance to ciprofloxacin (14%) were recorded.
cSeven isolates showed intermediate resistance to ciprofloxacin.
dResistance to florfenicol (6/8), colistin (1/8) and intermediate resistance to
ciprofloxacin (6/8) were recorded.
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identified [62] and ST313 appears to have occupied a
niche provided by HIV, malaria, and malnutrition in
SSA [63].
Implications and limitations
The results of this study have several implications in
clinical practices and in policy and research issues. The
comparatively lower proportion of ciprofloxacin resistant
isolates suggests the potential use of ciprofloxacin as an
empirical therapeutic agent. However, as there are evi-
dences of intermediate resistance to ciprofloxacin, alter-
native drugs should be included in the essential drug list
of the country so as to manage severe and life threaten-
ing infections. The fluoroquinolones were used to treat
children suffering from MDR Gram negative bacterial
infections [64] and azithromycin is an attractive alterna-
tive against MDR Salmonella [65,66]. An association be-
tween mass oral azithromycin treatment and a reduction
in all-cause and infectious mortalities in rural children
was recorded [67].
Policy and decision makers could make use of the evi-
dences as inputs to re-enforce the drug use policy and
to devise strategies and measures that could help reduce
the rates of emergence of drug resistant pathogens.
Apart from the active involvement of the regulatory bod-
ies and the long-arm of the law on drug smuggling and
over- the-counter sells of prescription-only drugs, educa-
tional initiatives could be of practical significance to re-
duce the rates of emergence of drug resistant pathogensin the country. Educational programs were reported to
be effective in improving the diagnostic qualities of
health workers and reducing unjustified prescriptions
[68]. Although information sources offer a framework to
base educational intervention measures, a regular train-
ing is more effective than guidelines alone [69].
The reservoirs and host ranges of the NTS isolates are
unknown and the factors associated with the emergence
of drug resistant strains are not adequately described.
Some of the strains (e.g. S. Concord) are becoming inter-
national concerns and containment of the problem
needs an international approach [15]. To this effect, a
large scale investigation into the pharmaco-epidemiology
of Salmonella is needed and research efforts should be
directed towards hypothesis driven preventive measures.
Apart from the small number of eligible studies, the
exact origins of the study subjects were not reported.
The pooled estimates were also derived from data col-
lected between 2000 and 2009. Therefore, as most pa-
tients could be from the urban areas where access to
health care facilities is relatively better than the rural
areas, the estimates are more applicable to the urban
than the rural population and the current proportions of
drug resistant isolates may be higher than the present
estimates.
Conclusion
The proportion of drug resistant Salmonella has in-
creased since the 1970s and a considerable proportion of
the isolates are multi-drug resistant. Ciprofloxacin could
be used as an empirical therapeutic agent. The third
generation cephalosporins are not useful against S. Con-
cord infections. Alternative drugs should be included in
the essential drug list and intervention measures should
be taken to re-enforce the drug use policy. Further large
scale studies are required to describe the pharmaco-
epidemiology of Salmonella in Ethiopia.
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